| __timestamp | CymaBay Therapeutics, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 7461000 |
| Thursday, January 1, 2015 | 8871000 | 11960000 |
| Friday, January 1, 2016 | 9645000 | 13108000 |
| Sunday, January 1, 2017 | 12387000 | 17501000 |
| Monday, January 1, 2018 | 14381000 | 22472000 |
| Tuesday, January 1, 2019 | 19238000 | 24286000 |
| Wednesday, January 1, 2020 | 17425000 | 29689000 |
| Friday, January 1, 2021 | 23040000 | 38837000 |
| Saturday, January 1, 2022 | 25116000 | 47489000 |
| Sunday, January 1, 2023 | 51953000 | 53379000 |
Unlocking the unknown
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. CymaBay Therapeutics, Inc. and Xencor, Inc. have been navigating this landscape since 2014. Over the past decade, Xencor has consistently outpaced CymaBay in SG&A spending, with a 40% higher average annual expense. However, CymaBay's recent surge in 2023, with a 107% increase from 2022, suggests a strategic pivot. Meanwhile, Xencor's expenses grew by 12% in the same period, indicating a more stable approach. This data highlights the contrasting strategies of these companies: CymaBay's aggressive expansion versus Xencor's steady growth. As the biotech industry evolves, these trends offer valuable insights into how companies balance innovation with cost management.
SG&A Efficiency Analysis: Comparing Vertex Pharmaceuticals Incorporated and CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Biogen Inc. and Xencor, Inc.
Genmab A/S vs Xencor, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Pharming Group N.V. or Xencor, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Soleno Therapeutics, Inc.
CymaBay Therapeutics, Inc. vs Geron Corporation: SG&A Expense Trends
Breaking Down SG&A Expenses: CymaBay Therapeutics, Inc. vs MiMedx Group, Inc.
Selling, General, and Administrative Costs: Soleno Therapeutics, Inc. vs Xencor, Inc.
Amphastar Pharmaceuticals, Inc. and Xencor, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Celldex Therapeutics, Inc. vs Xencor, Inc. Trends and Insights